NRG Oncology recently reported the results of the phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and ...

Shore Capital Partners has formed PhaseWell Research, a Nashville-based clinical research site company. No financial terms were disclosed. In conjunction with the formation, Carsten Bick has been ...

H-D Feminine Health, announces it has initiated the first randomized, placebo-controlled, double-blinded Phase 3 clinical trial cleared to proceed by the U.S. Food and Drug Administration (FDA) to ...

Discover BiomX's Q2 2025 updates, including progress in phage therapy trials BX004 & BX211, financial highlights, and key insights into upcoming ...

Private equity house LDC has backed the expansion plans of a North West-headquartered business which is the UK’s largest site ...

A Phase 1 human clinical trial to treat chronic spinal cord injury, the first of its kind in the world, has commenced to test ...

NRG Oncology recently reported the results of the National Cancer Institute sponsored phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and nivolumab with radiation therapy (RT) ...

Clinical trial updates in cancer care include a remote study in small cell lung cancer and new findings in ovarian, solid ...

Phase 1 study results published in Nature Medicine looks at a vaccine for patients with pancreatic and colorectal cancer. Dr Magnus Dillon, Clinician Scientist at The Institute of Cancer Research, ...

Cedars-Sinai physician-scientists joined peers from around the world at the Alzheimer's Association International Conference in July. The scientific presentations at the conference included data from ...

Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful ...

Key Points Alto Neuroscience (NYSE:ANRO) reported a net loss of $17.7 million (GAAP) in Q2 2025, with EPS of $(0.65) (GAAP). No revenue was reported, as the company remains in the clinical-stage ...